23 studies found for:    at1001
Show Display Options
Rank Status Study
1 Completed A Double-blind Placebo-controlled Study to Evaluate Larazotide Acetate for the Treatment of Celiac Disease
Condition: Celiac Disease
Interventions: Drug: Larazotide Acetate 0.5 mg;   Drug: Larazotide Acetate 1 mg;   Drug: Larazotide Acetate 2 mg;   Drug: placebo
2 Completed Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
Condition: Fabry Disease
Intervention: Drug: AT1001 150 mg
3 Completed A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)
Condition: Fabry Disease
Intervention: Drug: [14C] AT1001
4 Completed Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study
Condition: Fabry Disease
Intervention: Drug: AT1001
5 Completed A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
Condition: Fabry Disease
Interventions: Drug: GR181413A/AT1001 solution;   Drug: GR181413A/AT1001 capsule;   Other: Potable water;   Drug: Placebo capsule
6 Completed Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001
7 Completed Phase IIb Study to Study the Efficacy of AT1001 to Treat Celiac Disease
Condition: Celiac Disease
Interventions: Drug: AT-1001;   Drug: placebo
8 Completed Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride;   Drug: Placebo
9 Active, not recruiting Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride;   Biological: agalsidase
10 Completed A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
11 Completed Study of the Efficacy of AT1001 (Larazotide Acetate) to Treat Celiac Disease
Condition: Celiac Disease
Interventions: Drug: Larazotide acetate (AT1001);   Drug: Placebo
12 Completed Randomized, Double-Blind, Placebo-Controlled Study of Larazotide Acetate (AT-1001) in Active Celiac Disease
Condition: Celiac Disease
Interventions: Drug: larazotide acetate (AT-1001);   Drug: placebo
13 Completed Safety of AT-1001 in Healthy Volunteers
Condition: Healthy
Intervention: Drug: AT-1001
14 Completed Safety Study of AT1001 to Treat Celiac Disease.
Condition: Celiac Disease
Intervention: Drug: AT-1001
15 Completed Safety and Tolerability Study of AT1001 in Celiac Disease Subjects
Condition: Celiac Disease
Intervention: Drug: AT1001
16 Completed A Study of AT1001 in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
17 Completed A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
18 Completed A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
19 Completed A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers
Condition: Fabry Disease
Interventions: Drug: IV migalastat HCl;   Drug: IV placebo;   Drug: oral migalastat HCl
20 Recruiting Open-Label Phase 3 Long-Term Safety Study of Migalastat
Condition: Fabry Disease
Intervention: Drug: migalastat HCl 150mg

Previous Page Studies Shown (1-20) Next Page (21-23) Show next page of results
Indicates status has not been verified in more than two years